Navigation Links
TGen-led study reveals TWEAK-Fn14 as key drug target
Date:11/8/2013

PHOENIX, Ariz. Nov. 8, 2013 A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute (TGen).

TWEAK is a cytokine, or soluble protein, that controls many cellular activities and acts by binding to a cell surface receptor known as Fn14. TWEAK binding to Fn14 triggers a wide range of cellular activities, including blood clotting, inflammation, cell proliferation, cell migration, and the creation of new blood vessels.

While many of these activities are beneficial for example, helping to heal a cut excessive TWEAK-Fn14 activation also has been linked to tissue damage and degradation, including autoimmune diseases, as well as the survival, migration and invasion of cancer cells.

"Our results show that the TWEAK-Fn14 interaction is a viable drug target, and they provide the foundation for further exploration of this system in researching invasive cancers," said Dr. Nhan Tran, an Associate Professor in TGen's Cancer and Cell Biology Division.

"Because of its unique qualities and association with acute injuries, this drug-like molecule not only could benefit cancer patients, but also might be applied to patients with autoimmunity, heart disease like atherosclerosis, and rheumatoid arthritis," said Dr. Tran, the study's senior author.

The study Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-Inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis publishes in today's (Nov. 8) issue of The Journal of Biological Chemistry.

Overexpression of TWEAK-Fn14 has been linked to several types of cancer, including breast, pancreatic, esophageal, lung, liver and most important in this study glioblastoma.

By using protein-protein docking models, 129 small molecules were selected for screening, which identified four that inhibited the binding of TWEAK to Fn14.

One compound in particular, L524-0366, "completely suppressed TWEAK induced glioma cell migration without any potential cytotoxic effects," the study concluded.

"These results represent a significant step towards proving that the TWEAK-Fn14 interaction may be key to treating invasive glioblastoma brain tumors," said Dr. Michael Berens, TGen Deputy Director for Research Resources and Director of TGen's Cancer and Cell Biology Division.

"The next step will be to move this compound forward for drug development and eventual testing in clinical trials, where it might bring immediate benefit for patients," said Dr. Berens, a co-author of the study.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen-led study identifies genes associated with unhealthy liver function
2. Study using stem cells to improve organ transplantation to receive $12 million
3. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
4. Study finds that Americans want doctors guidance on genetic test results
5. New study assesses injuries seen in the emergency department to children of teenage parents
6. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
7. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
8. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
9. Physician shortage could be cut by new primary care models, study finds
10. Study: Access to health care increases prescription opioid availability and associated abuse
11. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: